Production (Stage)
SpringWorks Therapeutics, Inc.
SWTX
$46.48
$0.210.45%
NASDAQ
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Revenue | 656.52% | 3,058.47% | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | 730.42% | 3,417.33% | -- | -- | -- |
Cost of Revenue | 815.95% | 2,873.93% | -- | -- | -- |
Gross Profit | 724.82% | 3,462.97% | -- | -- | -- |
SG&A Expenses | 27.89% | 29.92% | 34.31% | 34.04% | 41.05% |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 25.59% | 34.80% | 33.35% | 31.14% | 29.91% |
Operating Income | 26.31% | 18.92% | 8.59% | -3.40% | -21.00% |
Income Before Tax | 25.11% | 20.60% | 9.77% | -1.06% | -17.31% |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | 25.11% | 20.60% | 9.77% | -1.06% | -17.31% |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | 25.11% | 20.60% | 9.77% | -1.06% | -17.31% |
EBIT | 26.31% | 18.92% | 8.59% | -3.40% | -21.00% |
EBITDA | 26.94% | 19.54% | 9.13% | -2.93% | -20.65% |
EPS Basic | 33.75% | 32.23% | 20.46% | 10.99% | -0.03% |
Normalized Basic EPS | 33.75% | 32.23% | 20.45% | 10.98% | -0.03% |
EPS Diluted | 33.75% | 32.23% | 20.46% | 10.99% | -0.03% |
Normalized Diluted EPS | 33.75% | 32.23% | 20.45% | 10.98% | -0.03% |
Average Basic Shares Outstanding | 12.71% | 17.37% | 15.19% | 14.91% | 16.56% |
Average Diluted Shares Outstanding | 12.71% | 17.37% | 15.19% | 14.91% | 16.56% |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |